Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients

A recent publication by our colleagues uses real world data to demonstrate the real world effectiveness of a recently approved therapy while maintaining safe outcomes. Extended-release calcifediol (ERC), active vitamin D hormones and analogs (AVD) and nutritional vitamin D (NVD) are commonly used therapies for treating secondary hyperparathyroidism (SHPT) in adults with stage 3–4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI). The study aimed to assess real-world experience of ERC and other vitamin D therapies in reducing PTH and increasing 25D using a robust and detailed medical chart review where clinical variables were required for evaluation of effectiveness.

Citation: Germain, M.J., Paul, S.K., Fadda, G. et al. Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients. BMC Nephrol 23, 362 (2022). https://doi.org/10.1186/s12882-022-02993-3